Showing results (51-60 of 144) with videos related to

Sort By:
Pageof 15
BJU International|December 3, 2022
A prospective descriptive 1-year study in France of all BCG therapy dispensations for non-muscle-invasive bladder cancerYann Neuzillet, Priscilla Leon, Thomas Seisen, et al.
Urology|January 4, 2020
Impact of MRI and Targeted Biopsies on Eligibility and Disease Reclassification in MRI-positive Candidates for Active Surveillance on Systematic BiopsiesGuillaume Ploussard, Jean-Baptiste Beauval, Marine Lesourd, et al.
World Journal of Urology|June 15, 2019
Performance of systematic, MRI-targeted biopsies alone or in combination for the prediction of unfavourable disease in MRI-positive low-risk prostate cancer patients eligible for active surveillanceGuillaume Ploussard, Jean-Baptiste Beauval, Marine Lesourd, et al.
The Journal of Urology|June 28, 2019
Added Value of Concomitant Systematic and Fusion Targeted Biopsies for Grade Group Prediction Based on Radical Prostatectomy Final Pathology on Positive Magnetic Resonance ImagingGuillaume Ploussard, Jean-Baptiste Beauval, Marine Lesourd, et al.
World Journal of Urology|October 16, 2019
Active surveillance eligibility of MRI-positive patients with grade group 2 prostate cancer: a pathological studyGuillaume Ploussard, Jean-Baptiste Beauval, Marine Lesourd, et al.
The French Journal of Urology|November 24, 2024
French AFU Cancer Committee Guidelines - Update 2024-2026: Upper urinary tract urothelial cancer (UTUC)Mathieu Roumiguié, Thomas Seisen, Alexandra Masson-Lecomte, et al.
The French Journal of Urology|November 24, 2024
French AFU Cancer Committee Guidelines - Update 2024-2026: Non-muscle invasive bladder cancer (NMIBC)Mathieu Roumiguié, Priscilla Leon, Evanguelos Xylinas, et al.
World Journal of Urology|September 9, 2024
Active surveillance for low-risk prostate cancer with high tumor burden at biopsy: lessons learned from a contemporary radical prostatectomy cohortJauffray Oliva, Vassili Anastay, Michael Baboudjian, et al.
Urologic Oncology|April 22, 2020
Intercenter reproducibility of software-based fusion biopsies for grade group prediction when targeting suspicious MRI lesionsCécile Manceau, Mathieu Roumiguié, Marine Lesourd, et al.
World Journal of Urology|January 2, 2023
Urinary biomarkers for bladder cancer diagnosis and NMIBC follow-up: a systematic reviewYanish Soorojebally, Yann Neuzillet, Mathieu Roumiguié, et al.
Pageof 15